|
|
|
|
|
|
|
|
|
26.03.26 - 15:13
|
AstraZeneca Sell (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 11500 Pence belassen. Die jüngsten leichten kommerziellen Rückschläge des Konkurrenten Alnylam Pharmaceutical bei Amvuttra zur Behandlung ......
|
|
|
26.03.26 - 14:46
|
Der BGH stärkt Patientenrechte bei AstraZeneca-Nebenwirkungen (Tichys Einblick)
|
|
|
Der Bundesgerichtshof (BGH) in Karlsruhe hat mit Urteil vom 9. März 2026 (Aktenzeichen VI ZR 335/24) vielen Betroffenen von Nebenwirkungen mit dem Impfstoff von Astra Zeneca neue Hoffnung gegeben. Die Klagen der von Nebenwirkungen betroffenen Zahnärztin, die zum Zeitpunkt der Impfung 40 Jahre alt war, scheiterten vor dem Landgericht in Mainz und dem Oberlandesgericht in
Der Beitrag Der BGH stärkt Patientenrechte bei AstraZeneca-Nebenwirkungen erschien zuerst auf Tichys Einblick....
|
|
|
26.03.26 - 07:06
|
Innate Pharma Reports Full Year 2025 Financial Results and Business Update (Business Wire)
|
|
|
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures
IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levels
Monalizumab PACIFIC-9 Phase 3 trial, partnered with AstraZeneca, continues to advance toward a planned H2 2026 data readout
IPH5201 (anti-CD39 antibody), partnered with AstraZeneca - Interim results of MATISSE Phase 2 trial in non-small cell lung cancer (NSCLC) have been selected for an oral presentation in one of the Clinical Trials Plenary Session Sessions at the AACR Annual Meeting 2026, on April 21
Cash position of €44.8 million1 as of December 31, 2025 with an anticipated cash runway until the end of Q3 2026
Conference call to be held today at 2:00 p.m. CET / 9:00 a.m. EDT
MARSEILLE, France--(BUSINESS WIRE...
|
|
|
23.03.26 - 14:48
|
Amani Therapeutics Closes $25 Million Series A to Advance AM-01, a Potential Best-in-Class Therapy for Serious Neuropsychiatric Disorders (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Amani Therapeutics, a newly formed biotechnology company backed by RTW Investments, today announced the closing of a $25 million Series A financing. The company also announced the appointment of its executive leadership team and the in-licensing of worldwide rights from AstraZeneca to a Phase 3–ready novel chemical entity (NCE), which is a component of Amani's lead program, AM-01.
Amani's mission is to develop highly efficacious, safer medicines for people living with serious neuropsychiatric disorders.
About AM-01
AM-01 is a fixed-dose combination product that includes clozapine and a Phase 3–ready NCE with worldwide rights in-licensed from AstraZeneca. Amani believes AM-01 has the potential to deliver clozapine's unmatched efficacy for patients with schizophrenia while addressing clozapine's most significant safety liability—severe neutropenia—and the burdensome blood-monitoring that limit its use.
Clozapine remains the only medication proven to meaningfully improv...
|
|
|
|
|
|
|
20.03.26 - 07:36
|
Global drug giants double down on China amid trend to build self-reliant supply chains (SCMP)
|
|
|
AstraZeneca said it would establish drug manufacturing facilities in Guangzhou and Shanghai as well as a separate innovation centre in Shanghai, joining a group of foreign players building new plants in China amid geopolitical tensions.
The moves are part of a US$15 billion commitment the British firm pledged to make in the world's second-largest drug market through 2030, unveiled during UK Prime Minister Keir Starmer's visit to Beijing in January.
China's manufacturing capabilities, integrated......
|
|
|
|
|
|
|
|
|
|
|
|
|
16.03.26 - 08:57
|
AstraZeneca Buy (DPA-AFX)
|
|
|
HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Astrazeneca mit einem Kursziel von 17000 Pence auf "Buy" belassen. Die Ziele für den operativen Cashflow des Pharmakonzerns stützten den Konsens für die Profitabilität im Jahr ......
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
